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Abstract Co-infection with hepatitis B virus (HBV) and
hepatitis C virus (HCV) is common and is associated with a
more severe liver disease and increased frequency in the
development of hepatocellular carcinoma (HCC). Here, we
demonstrated that HBV X protein (HBx) and HCV core protein
additively repress the universal cyclin-dependent kinase inhibitor
p21 gene at the transcription level. The transforming growth
factor-L responsive element and Sp1 site of the p21 promoter
were responsible for the effect of HCV core and HBx,
respectively. Furthermore, cell growth was additively stimulated
by them, suggesting that additive repression of the p21 might be
important to understand the cooperative development of HCC by
HBV and HCV. ß 2002 Published by Elsevier Science B.V.
on behalf of the Federation of European Biochemical Societies.
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1. Introduction
Human hepatitis B virus (HBV) and hepatitis C virus
(HCV) are two major etiologic agents of chronic hepatitis,
which is closely related to the development of hepatocellular
carcinoma (HCC). Co-infection with HBV and HCV is com-
mon and is associated with a more severe liver disease, in-
creased frequency in the development of HCC (approximately
¢ve-fold increase in risk), and resistance to interferon therapy
compared to those with single HBsAg or anti-HCV positivity
[1^4]. Despite of several epidermiological evidences, the mech-
anism by which HBV and HCV cooperatively cause HCC is
not understood.
Cell cycle progression is driven by the sequential activation
of cyclin-dependent kinases (CDKs), which are subject to reg-
ulation by positive (cyclins) and negative (CDK-inhibitory
proteins) e¡ectors [5]. One such negative e¡ector is the uni-
versal CDK inhibitor p21 [6]. While p21 can be transcription-
ally regulated by the p53 tumor suppressor protein [7] and is
thus believed to participate in the execution of p53 e¡ects, its
induction can also be activated by a rapidly growing list of
physiological and pathological factors, such as di¡erentiation
factors, growth factors, cytokines, and stress factors [8^11].
Through binding to cyclin/CDK complexes, p21 prevents
CDK-dependent phosphorylation, and subsequent inactiva-
tion of the retinoblastoma protein, which negatively regulates
cell cycle progression. p21 also interacts with proliferating cell
nuclear antigen (PCNA) to inhibit PCNA-dependent DNA
replication [12]. Thus, p21 exerts anti-proliferation activity
through inhibition of cyclin/CDK complexes and/or PCNA
functions [13,14].
HBV X protein (HBx) and HCV core protein are consid-
ered to play important roles during development of HCC.
Both proteins are known to stimulate cell proliferation by
repressing transcription of the p21 gene [15^18]. The initial
aim of this study was to investigate whether there is an addi-
tive e¡ect between HBx and HCV core on the repression of
p21 gene. Next, we tried to determine the mechanism by
which the two proteins additively repress the transcription
of p21 gene. Finally, we investigated whether the e¡ect is
connected to the additive cell growth stimulation.
2. Materials and methods
2.1. Plasmids
Plasmid pCI-neo-core K which encodes HCV core protein under
the human cytomegalovirus immediate-early promoter was described
previously [19]. Plasmid pCI-neo-IRES-HBx which encodes X region
(nt 1374^1839, accession number D23677) of the HBV DNA was
constructed by subcloning the PCR-ampli¢ed product into the XbaI
and NotI sites of pCI-neo (Promega) and inserting the encephalomyo-
carditis virus internal ribosome entry site (IRES) [20] in front of HBx.
The bicistronic expression vector pCI-neo-core-IRES-HBx was con-
structed by subcloning the HCV core gene in front of IRES in pCI-
neo-IRES-HBx, thus to translate HCV core protein cap-dependently
whereas HBx in an IRES-dependent manner. p21P, p21Pv1.9, and
other mutants of the p21 promoter were described by Datto et al.
[8]. pGL2-4UTLRE which contains four copies of transforming
growth factor (TGF)-L responsive element (TLRE) in pGL2-basic
(Promega) was described previously [8]. pGL2-2USp1 which contains
two copies of Sp1 binding site in the p21 promoter between 363 and
351 was described previously [15].
2.2. Transfection and luciferase assay
NIH 3T3 cells (2U105 cells per 60-mm diameter plate) were trans-
fected with a calcium phosphate-DNA precipitate containing 5 Wg
each of target and e¡ector plasmid DNAs as previously described
[21]. To control for variation in transfection e⁄ciency, 1 Wg of plas-
mid pCH110 (Pharmacia) containing the Escherichia coli lacZ gene
under control of the SV40 promoter was co-transfected. Forty-eight
hours after transfection, the level of expression from the target gene
(luciferase activity) was analyzed and values obtained were normalized
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to the L-galactosidase activity measured in the corresponding cell ex-
tracts. Each experiment was repeated at least three times.
2.3. Semi-quantitative reverse transcription (RT)-PCR and
Western blotting analysis
Total cellular RNA was extracted from cells 48 h after transfection
using Trizol (Gibco). For RT-PCR, 3 Wg of RNA was reverse-tran-
scribed with the corresponding antisense primer. One quarter of the
reverse-transcribed RNA was ampli¢ed with Taq polymerase (95‡C,
5 min; 30 cycles of 95‡C, 1 min^56‡C, 1 min^72‡C, 30 s; 72‡C, 5 min)
using the appropriate primer pairs. The primers for p21, p53, HBx,
and glyceraldehyde 3-phosphate dehydrogenase (G3PDH) were de-
scribed previously [15]. For the detection of HCV core transcripts,
sense primer 5P-TCC GGA TCC CTG TCA TCT TCT GTC CCT-
3P and antisense primer 5P-TCG CTT AGT GGA TCC TGG GGG
CAG-3P were used.
For Western blotting analysis, cells were lysed in bu¡er (50 mM
Tris^HCl, pH 8, 150 mM NaCl, 0.1% SDS, 1% NP-40) supplemented
with protease inhibitors. 10 Wg of cell extracts was separated by SDS^
PAGE and transferred onto a nitrocellulose membrane (Hybond
PVDF; Amersham). Western blotting was performed with either
anti-p53 monoclonal antibody (Santa Cruz), anti-p21 rabbit polyclon-
al IgG (Santa Cruz), or anti-actin monoclonal IgG (Santa Cruz), and
subsequently detected by chemiluminescent ECL kit (Amersham) as
recommended by the manufacturer.
2.4. Generation of stable cell lines and determination of cell growth rate
NIH 3T3 cells transfected with HBV core and/or HBx-expressing
plasmids were selected and ampli¢ed to obtain the stable cell lines as
described previously [19]. The expression level of transfected genes
was checked by either RT-PCR or Western blotting analysis. For
the determination of cell growth rate, 5U104 cells were plated in
six-well plates (Nunc) and the total cell number in each well was
counted after incubation for the indicated period.
3. Results and discussion
To examine whether HBx and HCV core additively repress
transcription of p21, we transiently transfected HBx and/or
HCV core-expressing plasmids into NIH 3T3 cells and per-
formed RT-PCR on the level of the endogenous p21 tran-
scripts (Fig. 1a). Consistently to the previous reports [15,16],
the NIH 3T3 cells expressing either HCV core (lane 2) or HBx
protein (lane 3) clearly showed the decrease of p21 transcrip-
tion compared to the control NIH 3T3 cells (lane 1) whereas
transcription of the housekeeping gene G3PDH was not af-
fected by the viral proteins. Interestingly, the transcription
level of p21 was much more repressed, almost undetectable
in HBx and HCV core co-expressing cells (lane 4). Similarly to
the RNA level, the endogenous p21 protein was also addi-
tively decreased by HBx and HCV core protein (Fig. 1b).
On the other hand, the p53 was not signi¢cantly a¡ected by
them at both RNA and protein levels (Fig. 1), suggesting that
the e¡ect is p53-independent.
Next, to examine whether HCV core and HBx additively
repress p21 at the transcription initiation level, we investigated
the e¡ect of them upon the p21 promoter using the p21-lucif-
erase reporter (p21P) which contains the luciferase gene under
the control of full-length p21 promoter. Initially, p21P and
viral protein-expressing constructs were co-transfected into
NIH 3T3 cells and luciferase assay was performed. Consis-
tently to the previous reports [15,16], HBx and HCV core
could separately repress the promoter activity of p21 approx-
imately three- and seven-fold, respectively (Fig. 2a). Co-ex-
pression of HBx and HCV core much more strongly represses
transcription of the p21-luciferase reporter construct, up to
15.9-fold, suggesting that the repression e¡ect of HBx and
HCV core on the p21 promoter-luciferase construct is addi-
tive.
We previously determined the region of the p21 promoter
responsible for the repression by HBx to a 61-bp region from
the transcriptional initiation site [15]. In this study, we tried to
determine the HCV core responsive element and the region
responsible for the additive e¡ect by HBx and HCV core. To
this end, a series of progressive 5P promoter deletion mutants
of the p21 promoter were tested (Fig. 2a). A deletion mutant
of p21 promoter, p21Pv1.9 which does not contain p53 bind-
ing sites (Fig. 2a), was additively repressed by HBx and HCV
core protein although the basal level of p21 promoter was
greatly decreased by the removal of p53 binding sites. This
result suggests that the additive repression of the p21 pro-
moter by HBx and HCV core is p53-independent. Further
deletion up to 393 did not a¡ect the additive e¡ect of HBx
and HCV core. However, the minimal promoter construct,
p21P smav1, which contains only 61 bp proximal to the tran-
scriptional initiation site was repressed by only HBx and thus
the e¡ect was not additive. Results from these experiments
suggest that HCV core represses p21 promoter through a
33-bp region between 393 and 361 whereas HBx through a
61-bp region from the transcriptional initiation site.
To precisely de¢ne the regions of the p21 promoter neces-
sary for the additive repression by HBx and HCV core, a
panel of the point-mutated p21 promoter between bases
393 and 344 [8] was examined. According to our previous
report [15], the sequence of the p21 promoter between 363
and 351 was essential for repression by HBx. In this study we
obtained a similar result with p21P 93-S mut#4 and mut#5
(Fig. 2b). p21P 93-S mut#1 and mut#3 were additively re-
pressed by HBx and HCV core in a similar manner to p21P
93-S. However, p21P 93-S mut#2 had almost completely lost
the ability to be repressed by HCV core (Fig. 2b). Considering
that p21P 93-S mut#2 has a mutated Sp1 site, the Sp1 site
might be responsible for the e¡ect of HCV core. However,
this hypothesis cannot explain why mutations in other Sp1
sites, for example Sp1-2, were not e¡ective. Therefore, the
complete loss of HCV core responsiveness in 93-S mut#2
might be due to another mutation which actually abolishes
the e¡ect.
Interestingly, the major HCV core responsive element in the
p21 promoter de¢ned above was exactly overlapped with the
Fig. 1. Additive repression of the p21 gene by HBx and core pro-
tein. a: NIH 3T3 cells were transfected with an empty vector (lane
1), HCV core (lane 2), HBx (lane 3), or HCV core and HBx (lane
4) expression vector and the RNA level were measured by semi-
quantitative RT-PCR. b: The protein level of p53, p21, and actin in
NIH 3T3 cells transfected as above was measured by Western blot-
ting.
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Fig. 2. Identi¢cation of HCV core and HBx responsive elements in the p21 promoter. a: Full-length and deletion p21 promoter constructs [8]
were co-transfected with HCV core and/or HBx-expressing plasmids into NIH 3T3 cells. Repression fold was calculated by comparing the lucif-
erase activity of HCV core and/or HBx-expressing cells with the basal activity of the control. The basal luciferase activity of the full-length p21
promoter is designated to 100%. The p53 binding sites are indicated by open boxes. b: 93-S mutant constructs, identical to the wild-type p21P
93-S sequence except the nucleotides shown for each mutant construct [8], were tested as above. The positions of transcription factor binding
sites are underlined.
Fig. 3. Repression of TLRE and Sp1 site by HCV core and HBx.
pGL2-4UTLRE [8] and pGL2-2USp1 [15] were co-transfected with
HBx and/or HCV core-expressing plasmids into NIH 3T3 cells. Re-
pression fold was calculated by dividing each luciferase activity by
the basal activity obtained with the control vector.
Fig. 4. Additive stimulation of cell growth by HCV core and HBx.
The growth fold of either NIH 3T3 cells or HCV core and/or HBx-
expressing stable cells for the indicated period was counted through
¢ve di¡erent experiments.
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TLRE which is known to mediate transcriptional activation of
the p21 gene by TGF-L [8]. More direct evidence that the Sp1
binding site is not responsible for the HCV core responsive-
ness was obtained with 93-S mut#2.3. This construct has a
mutation of bases 376 and 377 from CT to GG, thus main-
tains the consensus Sp1 binding site but showed a signi¢cantly
reduced ability to be activated by TGF-L [8]. The promoter
activity in 93-S mut#2.3 was not repressed by HCV core at
all, suggesting that destruction of the TLRE in both 93-S
mut#2 and 93-S mut#2.3 was responsible for the loss of
HCV core responsiveness. Therefore, we concluded that the
TLRE and the Sp1 sites between 363 and 351 of the p21
promoter are responsible for the e¡ect of HCV core and HBx,
respectively. Mutation in one of these sequences, which abol-
ishes the response by either HBx or HCV core, eventually
results in loss of the additive e¡ect, thereby both sequences
are necessary for the additive e¡ect.
To determine if the TLRE between 383 and 374 of p21
promoter de¢ned above is su⁄cient for the repression by
HCV core, this fragment was used in an attempt to confer
HCV core response to a heterologous promoter. pGL2 T+I
4UTLRE which has four copies of the TLRE inserted 5P of
the TATA box [8] was repressed by HCV core but not re-
sponsive to HBx (Fig. 3). In addition, pGL2-2USp1 [15]
which contains two copies of Sp1 binding site was responsive
to HBx but not to HCV core (Fig. 3). Both luciferase con-
structs were not additively repressed by HCV core and HBx,
as expected.
Because the tumor repressor p21 protein is an universal
inhibitor of cyclin^CDK complexes and DNA replication
that induces cell cycle arrest at the G1^S checkpoint, the
additive repression of p21 by HCV core and HBx may result
in additive growth stimulation of the cells. To test this possi-
bility, we prepared several NIH 3T3 cell lines stably express-
ing HCV core and/or HBx and measured their growth rates.
Five di¡erent cell lines with each plasmid were selected and
tested to show that di¡erences in their growth rates are not
just due to the chance selection of cell clones that grow at
di¡erent rates. In a similar pattern with the transient trans-
fection experiments, these cell lines expressed a decreased level
of the p21 protein compared to the parent cells (data not
shown). The growth rate of either HCV core- or HBx-express-
ing cell lines was, as expected, approximately two-fold faster
compared to that of the control cells (Fig. 4). In addition, the
growth stimulation e¡ect of HCV core and HBx was additive,
suggesting that the repression of p21 is properly re£ected by
the stimulation of cell growth.
In the present study, we provide a clue to understand the
mechanism for the synergistic e¡ect of HBV and HCV co-
infection on the progression from chronic hepatitis to HCC,
demonstrated by several epidermiological studies [1^4]. How-
ever, some contradictory data that additional infection of
HBV does not play a role in patients with chronic hepatitis
C were also reported [22]. Although our present study cannot
explain the latter situation, several possibilities can be consid-
ered. First, di¡erences in the conformation of HBx or HCV
core protein might be involved. Both proteins seem to exert
most of their functions through protein^protein interactions
and can be regulated by modi¢cations, such as phosphoryla-
tion [23,24]. Actually, according to our previous report, the
p21 regulatory activity of HCV core protein is a¡ected by the
phosphorylation status of the protein [16]. Therefore, di¡er-
ences in the amino acid sequences, especially at the phosphor-
ylation sites of the protein, could result in contradictory out-
comes both in vitro and in vivo. Another possibility to be
considered is the physiological status of host cells. Consider-
ing that both proteins function through cellular factors such
as Sp1 and TGF-L signalling molecules, as demonstrated in
the present study, the activity of these regulatory factors in
the host cell may a¡ect the ¢nal outcome of co-infection.
Further studies based on these possibilities may elucidate
the contradictory data concerning the synergistic e¡ect of
dual infection in vivo.
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